{"id":966766,"date":"2026-05-26T08:17:36","date_gmt":"2026-05-26T12:17:36","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/"},"modified":"2026-05-26T08:17:36","modified_gmt":"2026-05-26T12:17:36","slug":"pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/","title":{"rendered":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>Urges Stockholders to Vote \u201c<\/em><br \/>\n        <strong><br \/>\n          <em>FOR<\/em><br \/>\n        <\/strong><br \/>\n        <em>\u201d the Election of Pacira\u2019s Highly Qualified Nominees on the\u00a0<\/em><br \/>\n        <strong><br \/>\n          <em><br \/>\n            <u>BLUE<\/u><br \/>\n          <\/em><br \/>\n        <\/strong><br \/>\n        <em>\u00a0Proxy Card Today<\/em>\n      <\/p>\n<p>BRISBANE, Calif., May  26, 2026  (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX) (the \u201cCompany\u201d or \u201cPacira\u201d), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira\u2019s intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC\u2019s (\u201cDOMA Perpetual\u201d or \u201cDOMA\u201d)<sup>1<\/sup> recent inaccurate statements:<\/p>\n<p>DOMA\u2019s claims demonstrate a fundamental lack of understanding of Pacira\u2019s business, intellectual property (IP) strategy, Paragraph IV certifications and the biopharmaceutical industry at large. Pacira has <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=mJnTcGxuX02YPG0yuD_pHEtD7XDLvIRbUsZvb3vDEo-Xn3KKSyKpYpt1JZrsFb8oTf1AGcTTdatpfvnAcPN4V0oFzAzsrSktK-z_QkV11mzy92TxfBRlnXBGWJ9rU28RoByUrLOJ6lBlDDok8dK84fhXBZpghNcfS7OGdky6abZTBYL1UuuKYrlOqM8UZgcfAGzjCZTMS_9mRMihUlTxl_me8oljotWpwISqY0jSDjE0CM3PNigcNsbPyzbmHk2G\" rel=\"nofollow\" target=\"_blank\">clearly and frequently communicated<\/a> information regarding patent awards or infringement litigation to its stockholders and remains committed to doing so. Pacira strongly believes in the strength of the EXPAREL franchise, and its patent estate protects the Company from multiple directions.<\/p>\n<p>Here are the facts:<\/p>\n<ul>\n<li style=\"list-style-type:none\">\n<ul type=\"disc\">\n<li>Pacira\u2019s initial patent litigation commenced in 2021 and continued through 2024. <strong>There is no precedential value to this case<\/strong>, which only involved one EXPAREL patent (the \u2018495 patent). The \u2018495 patent was litigated in the United States District Court for the District of New Jersey.<\/li>\n<li>Following the Court\u2019s decision, Pacira secured a favorable reexamination of its \u2018495 patent from the U.S. Patent and Trademark Office (USPTO). Importantly, during this process, any weakness in this patent, which is from the Erucic Acid Family, was addressed through amended claims that added volume limitations and resolved other issues noted in the New Jersey Court\u2019s opinion. <strong>The \u2018495 patent has been reissued, and the Company believes it is now the strongest in the Erucic Acid Family of patents.<\/strong><\/li>\n<li>\n              <strong>None of EXPAREL\u2019s <\/strong><br \/>\n              <strong><br \/>\n                <em>\u201cOrange Book\u201d<\/em><br \/>\n              <\/strong><br \/>\n              <strong> listed patents are manufacturing patents.<\/strong> The 21 patents currently listed in the <em>Orange Book<\/em> comprise chemical composition and product-by-process patents covering the drug product, as well as method-of-use patents.\u00a0Manufacturing patents are not <em>Orange Book<\/em> listable by statute.<\/li>\n<li>Pacira engineered a new enhanced, larger-scale EXPAREL manufacturing process in San Diego that produced a more consistent and stable multivesicular liposome with improved yield and particle-size distribution. Because these results were unexpected, <strong>this was a patentable invention and became the \u2018940 patent, which provides protection into July 2044.<\/strong><\/li>\n<li>The \u2018940 patent is the first of a new<strong>, second family of EXPAREL patents that has never been previously challenged or litigated.\u00a0<\/strong>While the Company believes the Erucic Acid Family is strong, <strong>Pacira believes this second patent family is even stronger.<\/strong><\/li>\n<li>\n              <strong>The novelty of the \u2018940 patent and its family derives from the large dataset of <\/strong><br \/>\n              <strong><br \/>\n                <em>in<\/em><br \/>\n              <\/strong><br \/>\n              <strong><br \/>\n                <em>vitro<\/em><br \/>\n              <\/strong><br \/>\n              <strong> release assay (IVRA) batch data measured from every batch of EXPAREL<\/strong>. A separate USPTO examiner from the first family allowed the patent after considering the Court\u2019s opinion in the \u2018495 patent litigation.\u00a0<\/li>\n<li>\n              <strong>The Fresenius Kabi Settlement was a strategic win for stockholders<\/strong>, giving Pacira full exclusivity for EXPAREL through early 2030 and a gradual, capped market entry until 2039. This presents a clear runway to execute Pacira\u2019s diversification strategy without the rapid decline and disruption normally seen with generic entry.<\/li>\n<li>Pacira has taken critical steps to strengthen its IP and mitigate litigation risk, including <strong>expanding EXPAREL\u2019s patent estate to 21 <\/strong><strong><em>Orange Book<\/em><\/strong><strong> listed patents across two families<\/strong>, which provide exclusivity through the mid-2040s. The Company expects additional patents to be issued, which will be added to this robust patent estate.<\/li>\n<li>The potential for additional generic competition is a common dynamic with successful products like EXPAREL and is inherent to the biopharmaceutical industry. Pacira continues to innovate with the expectation that additional patents will be issued.<\/li>\n<li>Importantly, the two most recent Paragraph IV generic challenges <u>only<\/u> mean that Abbreviated New Drug Applications (ANDAs) have been filed with the <a href=\"https:\/\/www.fda.gov\/\" rel=\"nofollow\" target=\"_blank\">U.S. Food and Drug Administration<\/a> (FDA)<strong>.\u00a0It does not mean these generic challengers have FDA approvable products with demonstrated bioequivalence to EXPAREL that have been manufactured at commercial scale<\/strong>.\u00a0<\/li>\n<li>A Paragraph IV challenge is a gatekeeping standard for the FDA to accept an ANDA for filing and occurs before a substantive review takes place. The Company is in the early stages of this litigation, and as an active legal matter Pacira is limited in what it can say.<\/li>\n<li>Pacira has filed a patent infringement lawsuit in the United States District Court for the District of Delaware. <strong>The IVRA family has never been challenged or litigated, and the matter will be considered by a different court.<\/strong><\/li>\n<li>With the strength of Pacira\u2019s IP, ANDA filers must now overcome both families of EXPAREL patents, manufacture their products on a commercial scale, establish bioequivalence to EXPAREL and secure approval from the FDA. <strong>Pacira believes these are significant hurdles to overcome.<\/strong><\/li>\n<li>Publicly sharing details around Pacira\u2019s legal strategy, as DOMA is requesting, is <strong>not in the best interest<\/strong> of the Company\u2019s stockholders.<\/li>\n<li>\n              <strong>Pacira strongly believes in the strength of its intellectual property and believes the Company is taking the necessary steps to protect the interests of the business, patients and stockholders<\/strong>.<\/p>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p>DOMA\u2019s recent claims are another example of haphazard engagement and a concerning lack of fundamental understanding about biopharmaceutical patents. Don\u2019t let DOMA distract you with inaccurate information in their attempt to disrupt the positive momentum your board and management team have developed. Pacira is only in year two of its five-year, 5&#215;30 strategy, and execution is already delivering tangible results. The Company believes it has substantial upside potential supported by strong fundamentals and sustained growth trajectory. <strong>Pacira remains resolutely focused on maximizing stockholder value with the continued execution of its strategy.<\/strong><\/p>\n<p>Pacira encourages stockholders to vote the <strong><u>BLUE<\/u><\/strong> proxy card today \u201c<strong>FOR<\/strong>\u201d each of Pacira\u2019s three highly qualified board nominees and DISREGARD any white proxy card you may receive from DOMA.<\/p>\n<p align=\"center\">If you have questions or require assistance with voting your shares, please contact Pacira\u2019s proxy solicitor:<\/p>\n<p align=\"center\">D.F. King &amp; Co., Inc. at +1 (800) 714-3310 (toll-free from the U.S. and Canada) or +1 (646) 981-1286 (banks and brokers) or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KSDa182uR1aBuKiuK_emsm_UO2QjB0NgrQ6kfc7rsTBW2S6sO3Bf4QcAk4CfQ2KVImdkZuCXgrrgw6JqluiQkk8xUAzIZESkM-XKOL9ihpDtcu8ysM1qc_pde2AuFM4EiqqN56qFvF_Cj6J2C40a9mD0hEFebDx8nXX4aBjShk0EyLVSK1GD4K8V-NobbaByzJ6tYYex8FspXe3C-8N-vEkN0OzSKYyq85113z7HfOe1mJjUWM2VoOq35bIimfZUUlKT2-cGQhOaAv2GJ45R0A==\" rel=\"nofollow\" target=\"_blank\">PCRX@dfking.com<\/a>.<\/p>\n<p>\n        <strong>Advisors\u00a0<\/strong>\n      <\/p>\n<p>Goldman Sachs &amp; Co. LLC is acting as financial advisor and Perkins Coie LLP is acting as legal counsel to Pacira.\u00a0<\/p>\n<p>\n        <strong>About Pacira<\/strong>\n      <\/p>\n<p>Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL<sup>\u00ae<\/sup> (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA<sup>\u00ae<\/sup> (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera<sup>\u00ae<\/sup>\u00b0, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy, is in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WGUwXAyRHDwVBxpRKFD8nHfNnSkGBQYyuvBiNZ0KJbisSj0z_mlaBpmw99um59TCvKAUBBARxgJCHZGXYlnhxQ==\" rel=\"nofollow\" target=\"_blank\">www.pacira.com<\/a>.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>\n        <em>Any statements in this document about Pacira\u2019s future expectations, plans, trends, outlook, projections and prospects, and other statements containing the words \u201cbelieves,\u201d \u201canticipates,\u201d \u201cplans,\u201d \u201cestimates,\u201d \u201cexpects,\u201d \u201cintends,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201ccould,\u201d \u201ccan\u201d and similar expressions, constitute forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the \u201cExchange Act\u201d), and the Private Securities Litigation Reform Act of 1995, including, without limitation, statements related to: the 2026 Annual Meeting of Stockholders; Pacira\u2019s board of directors and the contributions of new directors and director nominees; \u20185&#215;30\u2019, our growth and business strategy, our future outlook, the strength and efficacy of our intellectual property protection and patent terms, our future growth potential and future financial and operating results and trends, our plans, objectives, expectations (financial or otherwise) and intentions, including our plans with respect to the repayment of our indebtedness, anticipated product portfolio and product development programs, strategic alliances, plans with respect to the Non-Opioids Prevent Addiction in the Nation (\u201cNOPAIN\u201d) Act and any other statements that are not historical facts. For this purpose, any statement that is not a statement of historical fact should be considered a forward-looking statement. We cannot assure you that our estimates, assumptions and expectations will prove to have been correct. Actual results may differ materially from these indicated by such forward-looking statements as a result of various important factors, including risks relating to, among others: risks associated with acquisitions, such as the risk that the acquired businesses and\/or assets will not be integrated successfully, that such integration may be more difficult, time-consuming or costly than expected or that the expected benefits of the transaction will not occur; our manufacturing and supply chain, global and United States economic conditions (including tariffs, inflation and rising interest rates), and our business, including our revenues, financial condition, cash flows and results of operations;<\/em>\u00a0<em>the success of our sales and manufacturing efforts in support of the commercialization of EXPAREL, ZILRETTA and\u00a0<\/em>iovera\u00b0<em>; the rate and degree of market acceptance of EXPAREL, ZILRETTA and iovera\u00b0; the size and growth of the potential markets for EXPAREL, ZILRETTA and iovera\u00b0 and our ability to serve those markets; our plans to expand the use of EXPAREL, ZILRETTA and iovera\u00b0 to additional indications and opportunities, and the timing and success of any related clinical trials for EXPAREL, ZILRETTA, iovera\u00b0 and any of our other product candidates, including but not limited to PCRX-201 (enekinragene inzadenovec) and PCRX-2002; the commercial success of EXPAREL, ZILRETTA and iovera\u00b0; the related timing<\/em>\u00a0<em>and success of United States Food and Drug Administration supplemental New Drug Applications and premarket notification 510(k)s; the related timing and success of European Medicines Agency Marketing Authorization Applications; our plans to evaluate, develop and pursue additional product candidates utilizing our proprietary high-capacity adenovirus (\u201cHCAd\u201d) vector platform; the approval of the commercialization of our products in other jurisdictions (by either us or our partners); clinical trials in support of an existing or potential HCAd-based product candidate; our commercialization and marketing capabilities; our ability to successfully complete capital projects; the outcome of any litigation; the recoverability of our deferred tax assets; assumptions associated with contingent consideration payments; assumptions used for estimated future cash flows associated with determining the fair value of the company; the anticipated funding or benefits of our share repurchase program; and factors discussed in the \u201cRisk Factors\u201d of Pacira\u2019s most recent Annual Report on Form 10-K and in other filings that it periodically makes with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d). In addition, the forward-looking statements included in this document represent Pacira\u2019s views as of the date of this document. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements, and as such Pacira anticipates that subsequent events and developments will cause its views to change. Except as required by applicable law, Pacira undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, and readers should not rely on these forward-looking statements as representing Pacira\u2019s views as of any date subsequent to the date of this document.<\/em><\/p>\n<p>\n        <em>These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Pacira\u2019s actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these statements. These factors include the matters discussed and referenced in the \u201cRisk Factors\u201d of Pacira\u2019s most recent Annual Report on Form 10-K and in other filings that Pacira periodically makes with the SEC.<\/em>\n      <\/p>\n<p>\n        <strong>Important Additional Information Regarding Proxy Solicitation<\/strong>\n      <\/p>\n<p>On April 28, 2026, Pacira filed a definitive proxy statement on Schedule 14A and\u00a0<strong><u>BLUE<\/u><\/strong>\u00a0proxy card with the SEC in connection with its solicitation of proxies for Pacira\u2019s 2026 annual meeting of stockholders (the \u201c2026 Proxy Statement,\u201d and such meeting the \u201c2026 Annual Meeting\u201d). This document is not a substitute for the 2026 Proxy Statement or any other document that Pacira has filed or may file with the SEC in connection with any solicitation by Pacira.\u00a0<strong>BEFORE MAKING ANY VOTING DECISION, INVESTORS AND STOCKHOLDERS OF PACIRA ARE URGED TO READ ALL RELEVANT DOCUMENTS FILED WITH OR<\/strong>\u00a0<strong>FURNISHED TO THE SEC, INCLUDING PACIRA\u2019S DEFINITIVE PROXY STATEMENT AND ANY AMENDMENTS AND SUPPLEMENTS THERETO, BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION.<\/strong> These documents, including the definitive 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=0_fAIIJkXcaRRqdi-96QKnqoLb_LrAu_JH_J50HwvM1WsjOZWCq-M06HG-mYSYvQ5owUNreDWEmdwMu65ymP4A==\" rel=\"nofollow\" target=\"_blank\">http:\/\/www.sec.gov<\/a>\u00a0and on Pacira\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sZXb5sLmy5EV7o27cmIOhWBVvvA_Gg2x8kJVfBsj1ebNDIkvQjSdB5IEwUETxMal81KsYLqDq9vQnlgEGqt-jNKTVl5Q01d7lSakO2lJVwR4PI1OP-p7IQN4SFiapxcn\" rel=\"nofollow\" target=\"_blank\">https:\/\/investor.pacira.com<\/a>.<\/p>\n<p>\n        <strong>Participants in the Solicitation<\/strong>\n      <\/p>\n<p>Pacira, its directors, director nominees, certain of its executive officers, and other employees may be deemed participants in the solicitation of proxies from stockholders in respect of the 2026 Annual Meeting. Information regarding the names of such persons and their respective interests in Pacira by security holdings or otherwise is set forth in the 2026 Proxy Statement. Please refer to the sections captioned \u201cDirector Compensation,\u201d \u201cExecutive Compensation,\u201d \u201cStock Ownership Information\u201d and \u201cAppendix D\u2014Supplemental Information Regarding Participants in the Solicitation\u201d in the 2026 Proxy Statement. To the extent holdings of Pacira\u2019s directors, director nominees, and executive officers who may be deemed to be participants in the solicitation in Pacira\u2019s securities have changed since the amounts described in the 2026 Proxy Statement, such changes have been reflected on Initial Statements of Beneficial Ownership of Securities on Form 3 or Statements of Changes in Beneficial Ownership of Securities on Form 4 filed with the SEC, as applicable.<\/p>\n<p>Additional information can also be found in Pacira\u2019s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=O4uHe9pHVvu1399wfHxg0BuVpIS0gmmGgqHS4FZ_zd7BhhKwpsx7gh4RKJZE0tKTc0r-NtRbEhIOU4M_V_5UwLecFuObpu5xBBxe_UXFk9TXjhmmQFeul1MyuNlucgrS-fjCOsFqgtdAeVODgcIu5X4gWy12-EVIIFxX19UMMnMp2HdHtiLy7OOZHAfNtmXX1znqGo1mxtV2GSf98tpEiirH32hPCgFUHaPVfhb6LoATqvD-ngcGg1NmXQHNryvNSBxEojIOydi95cN7Lgvw-8zqy7ma1qty0ep0WLZpCv5YNWFckyFa3FV00eIgem4zFcJIO-cAba6nH1_o5OaHwvKvUqVwQXkZPSXsBXViYYd4PAIx1Koi1LppGEQWCKgi\" rel=\"nofollow\" target=\"_blank\">February 26, 2026<\/a>. Details concerning potential participants in the solicitation, including Pacira\u2019s director nominees for election at the 2026 Annual Meeting, are also included in the 2026 Proxy Statement. These documents, including the 2026 Proxy Statement (and any amendments or supplements thereto) and other documents filed by Pacira with the SEC, are, or will be when filed, available for no charge on the SEC\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sZXb5sLmy5EV7o27cmIOhT9q_pX8pJ8iTOLIR5hKe6iSc7sna91inUanNSk7sbGdGpksHDXUw8Cs3k4mb-KK38RizFDfgN3hrengJNVJZNk=\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.sec.gov<\/a> and on Pacira\u2019s investor relations website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sZXb5sLmy5EV7o27cmIOhWBVvvA_Gg2x8kJVfBsj1ebFrn7UXuYaQCU_g9FEbqZjvGw4pDqKw5N93Gf7heVJ8uSiIcocN7W1nYpIor5CL47R6CY9x4hze7LbbE2-6owZ\" rel=\"nofollow\" target=\"_blank\">https:\/\/investor.pacira.com<\/a>.<\/p>\n<p>\n        \n      <\/p>\n<p>________________________________<br \/><sup>\u00b9 DOMA Perpetual Capital Management LLC is affiliated with certain other persons and entities identified in DOMA Perpetual\u2019s definitive proxy solicitation materials dated May 13, 2026.<\/sup><\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NTk4NzZmZDYtZjllMC00MGJkLWFiNTYtY2EwYzFkZjE4ZmRiLTEwMjA0ODQtMjAyNi0wNS0yNi1lbg==\/tiny\/Pacira-Pharmaceuticals-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\">\n<pre>Investor Contact: Susan Mesco, (973) 451-4030 susan.mesco@pacira.com\r\nMedia Contact: Kim Hamilton, (973) 254-4644 kim.hamilton@pacira.com<\/pre>\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Urges Stockholders to Vote \u201c FOR \u201d the Election of Pacira\u2019s Highly Qualified Nominees on the\u00a0 BLUE \u00a0Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX) (the \u201cCompany\u201d or \u201cPacira\u201d), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira\u2019s intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC\u2019s (\u201cDOMA Perpetual\u201d or \u201cDOMA\u201d)1 recent inaccurate statements: DOMA\u2019s claims demonstrate a fundamental lack of understanding of Pacira\u2019s business, intellectual property (IP) strategy, Paragraph IV certifications and the biopharmaceutical industry at large. Pacira has clearly and frequently communicated information regarding patent awards or &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-966766","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Urges Stockholders to Vote \u201c FOR \u201d the Election of Pacira\u2019s Highly Qualified Nominees on the\u00a0 BLUE \u00a0Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX) (the \u201cCompany\u201d or \u201cPacira\u201d), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira\u2019s intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC\u2019s (\u201cDOMA Perpetual\u201d or \u201cDOMA\u201d)1 recent inaccurate statements: DOMA\u2019s claims demonstrate a fundamental lack of understanding of Pacira\u2019s business, intellectual property (IP) strategy, Paragraph IV certifications and the biopharmaceutical industry at large. Pacira has clearly and frequently communicated information regarding patent awards or &hellip; Continue reading &quot;Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T12:17:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"12 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy\",\"datePublished\":\"2026-05-26T12:17:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/\"},\"wordCount\":2398,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/\",\"name\":\"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\",\"datePublished\":\"2026-05-26T12:17:36+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/","og_locale":"en_US","og_type":"article","og_title":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk","og_description":"Urges Stockholders to Vote \u201c FOR \u201d the Election of Pacira\u2019s Highly Qualified Nominees on the\u00a0 BLUE \u00a0Proxy Card Today BRISBANE, Calif., May 26, 2026 (GLOBE NEWSWIRE) &#8212; Pacira BioSciences, Inc. (Nasdaq: PCRX) (the \u201cCompany\u201d or \u201cPacira\u201d), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today issued the following statement with important facts stockholders should know regarding Pacira\u2019s intellectual property (IP) strategy, and DOMA Perpetual Capital Management LLC\u2019s (\u201cDOMA Perpetual\u201d or \u201cDOMA\u201d)1 recent inaccurate statements: DOMA\u2019s claims demonstrate a fundamental lack of understanding of Pacira\u2019s business, intellectual property (IP) strategy, Paragraph IV certifications and the biopharmaceutical industry at large. Pacira has clearly and frequently communicated information regarding patent awards or &hellip; Continue reading \"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-26T12:17:36+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"12 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy","datePublished":"2026-05-26T12:17:36+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/"},"wordCount":2398,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/","name":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=","datePublished":"2026-05-26T12:17:36+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTcyNjEyNSM3NjE5ODY5IzIwMDg5MTE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pacira-biosciences-sets-the-record-straight-regarding-domas-misleading-statements-about-paciras-intellectual-property-strategy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pacira BioSciences Sets the Record Straight Regarding DOMA\u2019s Misleading Statements About Pacira\u2019s Intellectual Property Strategy"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966766","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=966766"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/966766\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=966766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=966766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=966766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}